Novo to invest $400M in China insulin plant

Following other drugmakers' moves into China, Danish insulin giant Novo Nordisk has announced a major investment in a new insulin production plant in Tianjin. The plant has been designated the company's primary production base in the Asia Pacific region and will supply both China and export markets.

Biggest project outside Denmark

The cost of the project will amount to nearly $400.0 million and will create close to 500 new jobs in Tianjin. It is one of the largest investments in Novo Nordisk's history, and the biggest single one outside Denmark.